Search Results - "Iversen, Aske Thorn"

Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases by Ward, Daniel, Nyboe Andersen, Nynne, Gørtz, Sanne, Thorn Iversen, Aske, Højgaard Allin, Kristine, Beaugerie, Laurent, Kirchgesner, Julien, Jess, Tine

“…Tumor necrosis factor inhibitors (anti-TNF) are effective therapies for several immune-mediated inflammatory diseases (IMIDs). However, case reports have…”
Get full text

Risk of anorectal cancer in patients with Crohn's disease and perianal fistula: a nationwide Danish cohort study by El‐Hussuna, Alaa, Lemser, Camilla Engel, Iversen, Aske Thorn, Allin, Kristine Højgaard, Jess, Tine

“…Aim Patients with Crohn's disease (CD) often suffer from perianal fistulizing disease. Their risk of anorectal cancer remains uncertain. We aimed to examine…”
Get full text

Risk of cancer in patients with bile acid diarrhoea: a Danish nationwide matched cohort study by Nyboe Andersen, Nynne, Wildt, Signe, Iversen, Aske Thorn, Poulsen, Gry, Jess, Tine, Munck, Lars Kristian, Borup, Christian

“…ObjectiveBile acid diarrhoea is a common cause of chronic diarrhoea. Increased levels of potentially carcinogenic bile acids in faeces, theoretically, may…”
Get full text

Rectal Cancer Risk After Colectomy in Patients With Inflammatory Bowel Disease—A Population-Based Danish Cohort Study 1978–2018 by Akimenko, Elena, Bjerrum, Jacob Tveiten, Iversen, Aske Thorn, Allin, Kristine H., Jess, Tine

“…Selected patient groups with ulcerative colitis and Crohn's disease are at increased risk of colorectal cancer. Surveillance guidelines rarely cover patients…”
Get full text

Semaglutide 2.4 mg in People With or Without Antidepressants at Baseline: A Post-Hoc Analysis by Kushner, Robert, FINK-JENSEN, Anders, Frenkel, Ofir, McGowan, Barbara, Iversen, Aske Thorn, Overvad, Maria, Wadden, Thomas

Get full text

Effect of Semaglutide 2.4 mg on Use of Antihypertensive and Lipid-lowering Treatment in STEP Trials by Knight, Michael, Adelborg, Kasper, Clements, Jennifer, Iversen, Aske Thorn, Laursen, Peter, Tchang, Beverly, Traina, Andrea

“…Background: Semaglutide 2.4 mg is a GLP-1 receptor agonist approved for chronic weight management in people with overweight/ obesity. The objective of this…”
Get full text

The Underlying Causes of Secondary Bile Acid Diarrhea May Confound Cancer Risk by Borup, Christian, Nyboe Andersen, Nynne, Wildt, Signe, Iversen, Aske Thorn, Juul Poulsen, Gry, Jess, Tine, Munck, Lars Kristian

Get full text

OS-088 - Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial by Weghuber, Daniel, Gies, Inge, Gluud, Lise Lotte, Iversen, Aske Thorn, Jara, Maximilian, Schmidt, Signe, Sørrig, Rasmus, Wabitsch, Martin, Noureddin, Mazen

Get full text

Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial by Weghuber, Daniel, Gies, Inge, Gluud, Lise Lotte, Iversen, Aske Thorn, Jara, Maximilian, Schmidt, Signe, Sørrig, Rasmus, Wabitsch, Martin, Noureddin, Mazen

Get full text

Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg by Kelly, Aaron S., Arslanian, Silva, Hesse, Dan, Iversen, Aske Thorn, Körner, Antje, Schmidt, Signe, Sørrig, Rasmus, Weghuber, Daniel, Jastreboff, Ania M.

“…Objective The aim of this study was to examine how improvement in BMI with the glucagon‐like peptide‐1 receptor agonist semaglutide translated to changes in…”
Get full text

Instrumental Variable methods to target Hypothetical Estimands with longitudinal repeated measures data: Application to the STEP 1 trial by Bowden, Jack, Madsen, Jesper, Goldman, Bryan, Iversen, Aske Thorn, Liang, Xiaoran, Vansteelandt, Stijn

“…The STEP 1 randomized trial evaluated the effect of taking semaglutide vs placebo on body weight over a 68 week duration. As with any study evaluating an…”
Get full text